Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

This study analyzed pexidartinib-associated adverse events from FDA data and reported common events such as hepatic issues and systemic reactions. It highlighted sex-specific susceptibilities and reinforced the need for risk mitigation and long-term monitoring in tenosynovial giant cell tumor management.

This review examines the traditional uses and biological activities of Glycyrrhiza glabra in Ayurveda, but reports no new clinical results; the authors identify a gap in evidence supporting its medicinal potential.

This review discusses biotin's role in nutrition and suggests no benefit to supplementing it for hair, nails, and skin in healthy individuals; it reports preliminary findings that high dosages may help some multiple sclerosis patients.

This meta-analysis found that rheumatoid arthritis patients experience poorer sleep quality compared to healthy controls, including reduced total sleep time and efficiency, longer sleep latency, and increased wakefulness after sleep onset.

This study found that dermatological infectious diseases, particularly cutaneous leishmaniasis, were the most common among Syrian refugees in the surveyed region, highlighting the need for improved preventive health services.

This study confirms known risks of cladribine and reveals potential new safety concerns, emphasizing the need for careful monitoring for early acute toxicity.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

This study identified disproportionate reporting of several serious unknown or less documented adverse events associated with biologics for severe asthma, suggesting the need for further safety assessments.

In this review, the potential medicinal benefits of Adiantum capillus-veneris L. (a plant used in traditional medicine) were highlighted, particularly its antioxidant, antimicrobial, and anti-inflammatory effects, although the authors noted the need for more research on its impact on respiratory diseases.

In a real-world registry study, ripretinib showed effectiveness with a median progression-free survival of 7.70 months and a tolerable safety profile in Chinese patients using it as a fourth-line treatment for advanced GIST, particularly benefiting those with non-gastric tumors.

In this study, 60 mg/day of Cepharanthine significantly reduced the time to a negative COVID-19 test among de novo infected patients with good compliance, though 120 mg/day showed no such effect.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

This study found that finasteride use was associated with significantly higher odds of obstructive sleep apnea and insomnia compared to other medications.

This study found that veterans with obstructive sleep apnea were nearly twice as likely to develop herpes zoster compared to those without the condition.

This chapter discusses the composition, biocompatibility, and production methods of biomaterials like collagen, chitin, and silk for dermal substitutes, focusing on preclinical and clinical research, but reports no new clinical results.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

This study found that Carthamus caeruleus (L.) leaf extracts possess higher antioxidant and antibacterial activities compared to rhizome extracts, and are rich in phenolic and flavonoid compounds, suggesting potential use as a natural therapeutic agent.

In this study, phytochemical analysis and molecular docking suggested that bioactive compounds in several Ayurvedic herbs may interact persistently with hair growth and antifungal protein targets, indicating potential as plant-based treatments for dandruff and hair loss.

This study revealed significant signals of drug-related cognitive disorders in several medications that lack relevant FDA label warnings, suggesting a need for increased clinical awareness and potential label updates.

This study analyzed data from the FDA Adverse Event Reporting System and found that enfortumab vedotin, used for urothelial carcinoma, is linked to various cutaneous adverse events, including severe reactions like Stevens–Johnson syndrome, typically occurring early in treatment and predominantly affecting elderly male patients.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

In this study analyzing FDA data, researchers found that tralokinumab was associated with higher reports of conjunctivitis and keratitis compared to dupilumab, while dupilumab had more frequent injection site reactions, highlighting potential risks for clinical monitoring in atopic dermatitis treatments.

This pharmacovigilance study identified 64 drugs linked to hair loss, revealing specific demographic trends and timing patterns, and emphasized the importance of gender-specific monitoring and label updates to better convey real-world risks.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.

This retrospective study found that applying local skin precooling before scalp nerve block significantly reduced injection site pain during PRP mesotherapy for patients with androgenetic alopecia, compared to those who did not receive precooling, thus improving patient comfort and compliance.

This study examined data from the FDA Adverse Event Reporting System and found that finasteride use is linked with both known and previously unlisted adverse events, such as erectile dysfunction and post-5α reductase inhibitor syndrome, with variations observed by age and sex.